Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ascletis’ Ganovo gets CFDA approval for treatment of viral hepatitis C
Ganovo is the first Direct-acting Anti-viral Agent (DAA) developed by a domestic company in China and has been selected as a National Science and Technology Major Project for
Ganovo is the first Direct-acting Anti-viral Agent (DAA) developed by a domestic company in China and has been selected as a National Science and Technology Major Project for
In addition, BridgeBio announced that it was launching a new subsidiary, Origin Biosciences, with sufficient capital to support clinical development of ALXN1101 through potential regulatory approval and commercialization.
ADXS-NEO is being evaluated in an open-label, dose-escalation, multicenter Phase 1 clinical trial in the United States. The study is open to patients with metastatic non-small cell lung
Cellenkos submitted its IND application on May 11, 2018. The Phase I clinical trial of CK0801 will commence in the third quarter of 2018 at The University of
Results were presented at the OxalEurope, European Hyperoxaluria Consortium, taking place on 8 June 2018 in Naples, Italy. Updated interim data were from Part B of the Phase
Oncologie is committed to developing impactful cancer therapies to improve long–term survival of cancer patients worldwide. Building a pipeline of First and Best-in-Class clinical stage drug candidates through
Alliance awaits issue of the formal Marketing Authorisation from the MHRA in the coming weeks, with UK launch anticipated to be in the autumn of this year. Diclectin,
This round of financing was led by Yuexiu New Industrial Investment, followed by Sangel Biomedical Venture Capital, HuaKong Equity Investment and Qianhai Shenghui Investment. The proceeds will be
Additionally, all ranked secondary endpoints were met. The ongoing study evaluates upadacitinib, an investigational oral JAK1-selective inhibitor, as a monotherapy treatment compared to methotrexate monotherapy in adult patients
Each of the company’s current investors participated in the financing, including Atlas Venture, SR One, Lilly Ventures, Bill Gates, Pfizer Venture Investments, Lightstone Ventures, and Schrödinger. Bruce Booth,